OptimizeRx (OPRX) Competitors $14.07 +1.10 (+8.48%) As of 01:07 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OPRX vs. NEO, IIIV, IBTA, PRSU, RSKD, NRDS, PSFE, CARS, MEG, and MPLNShould you be buying OptimizeRx stock or one of its competitors? The main competitors of OptimizeRx include NeoGenomics (NEO), i3 Verticals (IIIV), Ibotta (IBTA), Pursuit Attractions and Hospitality (PRSU), Riskified (RSKD), NerdWallet (NRDS), Paysafe (PSFE), Cars.com (CARS), Montrose Environmental Group (MEG), and MultiPlan (MPLN). These companies are all part of the "business services" industry. OptimizeRx vs. Its Competitors NeoGenomics i3 Verticals Ibotta Pursuit Attractions and Hospitality Riskified NerdWallet Paysafe Cars.com Montrose Environmental Group MultiPlan OptimizeRx (NASDAQ:OPRX) and NeoGenomics (NASDAQ:NEO) are both small-cap business services companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations. Which has more risk and volatility, OPRX or NEO? OptimizeRx has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Comparatively, NeoGenomics has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500. Do insiders & institutionals have more ownership in OPRX or NEO? 76.5% of OptimizeRx shares are held by institutional investors. Comparatively, 98.5% of NeoGenomics shares are held by institutional investors. 5.6% of OptimizeRx shares are held by company insiders. Comparatively, 2.4% of NeoGenomics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has higher valuation and earnings, OPRX or NEO? OptimizeRx has higher earnings, but lower revenue than NeoGenomics. OptimizeRx is trading at a lower price-to-earnings ratio than NeoGenomics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOptimizeRx$94.37M2.76-$18.66M-$0.84-16.75NeoGenomics$660.57M1.35-$78.73M-$0.61-11.38 Does the media favor OPRX or NEO? In the previous week, NeoGenomics had 8 more articles in the media than OptimizeRx. MarketBeat recorded 9 mentions for NeoGenomics and 1 mentions for OptimizeRx. OptimizeRx's average media sentiment score of 1.42 beat NeoGenomics' score of 1.21 indicating that OptimizeRx is being referred to more favorably in the media. Company Overall Sentiment OptimizeRx Positive NeoGenomics Positive Is OPRX or NEO more profitable? NeoGenomics has a net margin of -11.54% compared to OptimizeRx's net margin of -16.33%. OptimizeRx's return on equity of -0.29% beat NeoGenomics' return on equity.Company Net Margins Return on Equity Return on Assets OptimizeRx-16.33% -0.29% -0.20% NeoGenomics -11.54%-2.21%-1.22% Do analysts rate OPRX or NEO? OptimizeRx presently has a consensus target price of $10.81, suggesting a potential downside of 23.15%. NeoGenomics has a consensus target price of $13.83, suggesting a potential upside of 99.33%. Given NeoGenomics' higher possible upside, analysts clearly believe NeoGenomics is more favorable than OptimizeRx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OptimizeRx 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.73NeoGenomics 0 Sell rating(s) 6 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.45 SummaryOptimizeRx and NeoGenomics tied by winning 8 of the 16 factors compared between the two stocks. Get OptimizeRx News Delivered to You Automatically Sign up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPRX vs. The Competition Export to ExcelMetricOptimizeRxCOMP IndustryComputer SectorNASDAQ ExchangeMarket Cap$260.60M$163.64B$28.18B$9.30BDividend YieldN/A1.31%3.14%4.03%P/E Ratio-16.7737.5132.9919.64Price / Sales2.7617.891,721.29188.30Price / CashN/A28.0137.6457.93Price / Book2.229.797.575.63Net Income-$18.66M$3.58B$779.73M$257.73M7 Day Performance3.91%-1.69%-0.34%0.07%1 Month Performance2.18%6.22%5.25%8.32%1 Year Performance33.87%43.08%52,756.65%13.78% OptimizeRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPRXOptimizeRx2.0066 of 5 stars$14.07+8.5%$10.81-23.2%+26.0%$260.60M$94.37M-16.77100Positive NewsNEONeoGenomics3.9884 of 5 stars$7.31-3.2%$13.83+89.2%-53.5%$971.64M$660.57M-11.982,200News CoveragePositive NewsIIIVi3 Verticals3.6845 of 5 stars$29.06+0.2%$29.57+1.8%+22.0%$963.29M$229.92M6.601,480High Trading VolumeIBTAIbotta3.2132 of 5 stars$35.30-3.2%$61.60+74.5%N/A$923.07M$367.25M23.85N/APRSUPursuit Attractions and Hospitality0.9558 of 5 stars$30.15-3.0%$29.67-1.6%N/A$878.19M$366.49M2.451,500Positive NewsRSKDRiskified1.0897 of 5 stars$5.14-3.4%$6.03+17.3%-18.2%$857.63M$327.52M-23.36780NRDSNerdWallet3.9354 of 5 stars$11.09-2.0%$15.00+35.3%-30.9%$843.48M$687.60M28.44770News CoveragePSFEPaysafe3.1973 of 5 stars$13.34-0.8%$16.95+27.1%-34.5%$805.50M$1.70B-667.003,300Gap UpCARSCars.com3.6893 of 5 stars$12.09-0.9%$18.30+51.4%-35.5%$775.04M$719.15M17.781,800MEGMontrose Environmental Group2.7465 of 5 stars$22.300.0%$31.80+42.6%-40.6%$773.34M$696.40M-9.613,410MPLNMultiPlan0.1652 of 5 stars$45.43+6.9%$26.25-42.2%N/A$734.65M$930.62M-0.48170 Related Companies and Tools Related Companies NeoGenomics Alternatives i3 Verticals Alternatives Ibotta Alternatives Pursuit Attractions and Hospitality Alternatives Riskified Alternatives NerdWallet Alternatives Paysafe Alternatives Cars.com Alternatives Montrose Environmental Group Alternatives MultiPlan Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OPRX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptimizeRx Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptimizeRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OPRX Stock Alerts